DOCSLIB.ORG

Reyoung Pharmaceutical Co,.Ltd. Products List Tel:86-533-3257894,Fax:86-533-3224277 No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reyoung Pharmaceutical Co,.Ltd. Products List Tel:86-533-3257894,Fax:86-533-3224277 No Reyoung Pharmaceutical Co,.Ltd. Products list Tel:86-533-3257894,Fax:86-533-3224277 No. Classfication Products name Strengths Powder for Injection Amoxicillin Sodium and Clavulanate Potassium for 0.6g, 1.2g Injection Amoxicillin Sodium and Flucloxacillin Sodium for 0.5g, 1.0g Injection Amoxicillin Sodium and Sulbactam Sodium for Injection 0.75g, 1.5g, 3.0g Amoxicillin Sodium for Injection 0.25g, 0.5g, 1.0g Ampicillin Sodium and Cloxacillin Sodium for Injection 0.5g, 1.0g Ampicillin Sodium and Oxacillin Sodium(2:1) for Injection 0.5g, 1.0g Ampicillin Sodium and Sulbactam Sodium for Injection 0.75g, 1.5g Ampicillin Sodium for Injection 0.25g, 0.5g, 1.0g Aspoxicillin for Injection 1.0g, 2.0g Azlocillin Sodium for Injection 0.5g, 1.0g, 2.0g Benzathine Penicillin for Injection 0.6mega, 1.2mega, 2.4mega 0.8mega, 1.0mega, 1.6mega, Benzylpenicillin Potassium for Injection 2.0mega, 5.0mega, 10mega Penicillin 0.8mega, 1.0mega, 1.6mega, Antibacterial Benzylpenicillin Sodium for Injection 2.0mega, 5.0mega, 10mega Cloxacillin Sodium for Injection 0.25g, 0.5g, 1.0g Flucloxacillin Sodium for Injection 0.25g, 0.5g,1.0g Fortified Procaine Penicillin for Injection 1.2mega, 2.0mega, 4.0mega Mezlocillin Sodium and Sulbactan Sodium for Injection 0.625g, 1.25g, 2.5g, 3.75g Mezlocillin Sodium for Injection 3.0g, 4.0g Oxacillin Sodium for Injection 0.5g, 1.0g Piperacillin Sodium and Sulbactam Sodium for Injection 1.25g, 2.5g Piperacillin Sodium and Tazobactam Sodium for Injection 1.125g, 2.25g, 4.5g Piperacillin Sodium for Injection 0.5g, 2.0g 0.4mega, 0.6mega, 0.8mega, Procaine Penicillin for Injection 1.0mega, 3.0mega Sulbenicillin Sodium for Injection 1.0g, 2.0g Ticarcillin Disodium and Clavulanate Potassium for 1.6g, 3.2g Injection Triple Penicillin for Injection 1.2mega, 2.4mega Cefalotin Sodium for Injection 1.0g, 2.0g Cefazolin Sodium for Injection 0.5g, 1.0g Cefminox Sodium for Injection 0.5g, 1.0g Cefonicid Sodium for Injection 0.5g, 1.0g Cefoperazone Sodium and Sulbactam Sodium for 1.0g, 1.5g, 2.0g Injection Cefoperazone Sodium for Injection 1.0g Cefotaxime Sodium for Injection 0.5g, 1.0g Cefotetan Disodium for Injection 1.0g, 2.0g Cephalosporin Cefoxitin Sodium for Injection 0.5g, 1.0g, 2.0g Antibacterial Cefozopran Hydrochloride for Injection 0.5g, 1.0g Cefpiramide Sodium for Injection 0.5g, 1.0g, 2.0g Cefpirome Sulfate for Injection 1.0g Cefradine for Injection 0.5g, 1.0g Ceftazidime for Injection 0.5g, 1.0g, 2.0g Ceftriaxone Sodium and Sulbactam Sodium for Injection 1.5g Ceftriaxone Sodium for Injection 0.5g, 1.0g Cefuroxime Sodium for Injection 0.75g, 1.50g Cefepime for Injection 0.5g, 1.0g Capreomycin Sulfate for Injection 0.75g, 1.0g Chloramphenicol Sodium Succinate for Injection 1.0g Doxycycline Hydrochloride for Injection 0.1g, 0.2g Erthromycin Lactobionate for Injection 0.25g, 0.3g, 1.0g Fosfomycin Sodium for Injection 1.0g, 2.0g, 4.0g Imipenem and Cilastatin Sodium for Injection 0.5g, 1.0g Kitasamycin Tartrate for Injection 0.2mega Generic Powder for Injection Generic Powder Lysine Acetylsalicylate for Injection 0.9g, 1.8g for Injection Meclofenoxate Hydrochloride for Injection 0.1g, 0.25g Propacetamol Hydrochloride for Injection 1.0g, 2.0g Rifampicin for Injection 0.45g Streptomycin Sulfate for Injection 1.0g, 5.0g Vancomycin for Injection 0.5g, 1.0g Kanamycin for Injection 1.0g Meropenem for Injection 0.5g, 1.0g Lyophilized Powder for Injection Alginric Sodium Diester for Injection 100mg Aminophylline for Injection 250mg Asarone for Injection 8mg Buflomedil Hydrochloride for Injection 50mg Citicoline Sodium for Injection 0.25g Cardiocerebral Isosorbide Mononitrate for Injection 25mg vascular Ligustrazine Phosphate for Injection 50mg Meglumine Adenosine Cyclophosphate for Injection 30mg, 60mg Nicergoline for Injection 4mg, 8mg Nimodipine for Injection 2mg, 4mg Ozagrel Sodium for Injection 40mg, 60mg, 80mg Puerarin for Injection 100mg, 200mg Vinpocetine for Injection 10mg Azithromycin for Injection 250mg, 500mg Licorice acid anhydride 20mg glycine 200mg mgcyteine hydrochloride 10mg Licorice acid anhydride 40mg Compound Glycyrrhizin for Injection glycine 400mg mgcyteine hydrochloride 20mg Licorice acid anhydride 80mg glycine 800mg mgcyteine hydrochloride 40mg Diammonium Glycyrrhizin for Injection 150mg Diclofenac Sodium and Lidocaine Hydrochloride for 75mg+20mg Injection Generic Doxofylline for Injection 200mg Lyophilized Enoxacin Gluconate for Injection 200mg Powder for Esomeprazole Sodium for Injection 20mg, 40mg Injection Gastrodin Talolets for Injection 200mg Ketoprofen for Injection 100mg Matrine for Injection 150mg Mecobablamin for Injection 0.5mg Omeprazole Sodium for Injection 40mg Pantoprazole Sodium for Injection 40mg Pefloxacin Mesylate for Injection 200mg, 400mg Piracetam for Injection 50mg, 100mg, 200mg, 400mg Potassium Sodium Dehydroandroan Drographolide 200mg, 800mg Succinate for Injection Tramadol Hydrochloride for Injection 100mg Tranexamic Acid for Injection 250mg, 500mg Tropisetron Hydrochloride for Injection 5mg Vitamin B Complex for Injection(B1:B6:B12) 50mg:250mg:5mg Lansoprazole for Injection 30mg Levocarnitine for Injection 1.0g Solid Preparation 312.5mg(4:1), 375mg(2:1) Amoxicillin and Clavulanate Potassium Tablets 457mg(7:1), 562.5mg(8:1) 625mg(4:1), 1000mg(7:1) Amoxicillin Capsules 250mg, 500mg Amoxicillin Chewable Tablets 250mg Amoxicillin Dispersible Tablets 125mg, 250mg Amoxicillin Film-coated Tablets 500mg, 1000mg Amoxicillin Tablets 250mg, 500mg, 1000mg Ampicillin and Cloxacillin Sodium Capsules 250mg+250mg Ampicillin Capsules 250mg, 500mg Ampicillin Tablets 250mg, 500mg, 1000mg Cloxacillin Sodium Capsules 250mg, 500mg Oxacillin Sodium Capsules 250mg Oxacillin Sodium Tablets 250mg Penicillin V Potassium Capsules 250mg Penicillin V Potassium Tablets 250mg, 500mg Flucloxacillin Capsules 250mg, 500mg 125mg/5ml, 60ml 125mg/5ml, 100ml Amoxicillin for Oral Suspension 250mg/5ml, 60ml 250mg/5ml, 100ml 125mg/5ml, 60ml 125mg/5ml, 100ml Ampicillin for Oral Suspension 250mg/5ml, 60ml Penicillin 250mg/5ml, 100ml Antibacterial 125mg/5ml, 60ml 125mg/5ml, 100ml Cloxacillin Sodium for Oral Suspension 250mg/5ml, 60ml 250mg/5ml, 100ml 125mg/5ml, 60ml 125mg/5ml, 100ml Oxacillin Sodium for Oral Suspension 250mg/5ml, 60ml 250mg/5ml, 100ml Cefadroxil Capsules 250mg, 500mg Cefadroxil Tablets 250mg, 500mg Cefalexin Capsules 125mg, 250mg, 500mg Cefixime Tablets 100mg, 200mg, 400mg Cephalosporin Cefixime Dispersible Tablets 100mg, 200mg, 400mg Cefixime Capsules 100mg, 200mg, 400mg Antibacterial Cefixime Granules 100mg, 200mg, 400mg Cefuroxime Axetil Tablets 125mg, 250mg, 500mg Cefradine Capsules 250mg, 500mg Cefradine Tablets 250mg, 500mg Cefotiam Hexetil Hydrochloride Tablets 100mg, 200mg Acetylspiramycin Tablets 100mg, 200mg Aciclovir Tablets 100mg, 200mg Alogliptin Benzoate Tablets 12.5mg, 25mg Amfebutamone Hydrochloride Sustained-release Tablets 150mg Aspirin Tablets 100mg, 300mg, 500mg Atorvastatin Calcium Tablets 10mg, 20mg Berberine Hydrochloride Tablets 100mg Benazepril Hydrochloride Tablets 10mg Bifendate Tablets 25mg Camostat Mesilate Tablets 100mg Carbamazepin Tablets 200mg Choline Magnesium Trisalicylate Tablets 327.5mg Citicoline Sodium Capsules 40mg, 100mg Ciprofloxacin Film-Coated Tablets 250mg, 500mg, 750mg Clinofibrate Dispersible Tablets 200mg Clotrimazole Effervescent Tablets 150mg Co-trimoxazole Tablets 480mg, 960mg Aluminium hydroxide 245mg Magnesium trisilicate 105mg Compound Aluminium Hydroxide Tablets Extractum Belladonnae liquidum 0.0026ml Aminopyrine 150mg Phenacetin 150mg Compound Aminopyrine Phenacetin Tablets Caffeine 50mg Phenobarbital 15mg Glycyrrhizin 25mg Compound Glycyrrhizin Capsules Glycyrrhizic acid 25mg Methionine 25mg Compound Paracetamol and Amantadine Hydrochloride Acetaminophen 250mg Capsules Amantadine Hydrochloride 100mg Acetaminophen 126mg Compound Paracetamol Tablets Acetylsalicylic acid 230mg Caffeine 30mg Compound Vitamin B Tablets Compound Desloratadine Tablets 5mg Generic Solid Preparation Diclofenac Sodium and Codeine Phosphate Tablets 25mg+15mg Diclofenac Sodium Entric-coated Tablets 25mg, 50mg, 100mg Domiphen Bromide Buccal Tablets 500mg Doxazosin Mesylate Tablets 1mg, 4mg Escitalopram Oxalate Tablets 5mg, 10mg, 20mg Fluoxetine Tablets 20mg Gabapentin Capsules 100mg, 300mg Gegentang Tablets 400mg Glibenclamide Tablets 5mg, 20mg Glipizide Tablets 5mg Griseofulvin Tablets 125mg, 250mg, 500mg Halazon Tablets 20mg Ibuprofen Sugar-coated Tablets 200mg, 400mg, 600mg Indobufen Tablets 200mg Isosorbide Mononitrate Tablets 20mg Kitasamycin Tablets 0.1mega Levocetirizine Dihydrochloride Tablets 5mg Linezolid Tablets 600mg Lincomycin Hydrochloride Capsules 250mg, 500mg Generic Solid Memantine Hydrochloride Tablets 100mg Preparation Menadiol Diacetate Tablets 2mg, 4mg Menthol Throat Tablets Compound Metamizole Sodium Tablets 500mg Metformin Hydrochloride and Glibenclamide Capsules 250mg+1.25mg Metformin Hydrochloride Tablets 500mg Methyltestosterone Tablets 5mg Montelukast Sodium Chewable Tablets 4mg, 5mg Montelukast Tablets 10mg Naproxen Sodium Tablets 275mg, 550mg Naproxen Tablets 100mg, 250mg Nitrendipine Tablets 10mg Nebivolol Hydrochloride Tablets 5mg Neutral Proteinase Enteric-coated Tablets 10mg Norfloxacin Capsules 0.1g Omeprazole Capsules 20mg Otilonium Bromide Capsules 40mg Otilonium Bromide Dispersible Tablets 40mg Otilonium Bromide Tablets 40mg Olanzapine Tablets 5mg, 10mg Oxytetracycline Tablets 250mg, 500mg Paracetamol Tablets 100mg, 500mg Perphenaine Tablets 2mg, 4mg Piracetam Tablets 400mg Primidone Tablets 250mg Potassium Chloride Tablets 250mg Quinine Sulfate
Load more

Recommended publications
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • WO 2016/120258 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2016/120258 A l 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/20 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 16/05 1545 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 January 2016 (26.01 .2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 264/MUM/2015 27 January 2015 (27.01 .2015) IN kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: JANSSEN PHARMACEUTICA NV TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).
    [Show full text]
  • The Antibiotics Composition Comprising Beta-Lactam
    (19) & (11) EP 2 062 581 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 31/545 (2006.01) A61K 31/546 (2006.01) A61K 31/43 (2006.01) A61K 31/431 (2006.01) (2006.01) (2006.01) (21) Application number: 07785338.0 A61K 31/424 A61K 31/7036 A61K 47/18 (2006.01) A61K 47/12 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.08.2007 A61K 47/02 A61K 47/04 A61K 9/08 (2006.01) A61K 9/19 (2006.01) A61K 9/72 (2006.01) A61P 31/04 (2006.01) A61P 31/00 (2006.01) (86) International application number: PCT/CN2007/002438 (87) International publication number: WO 2008/025226 (06.03.2008 Gazette 2008/10) (84) Designated Contracting States: (71) Applicant: Tianjin Hemey Bio-Tech Co., Ltd. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tianjin 300457 (CN) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: ZHANG, Hesheng Designated Extension States: Tianjin 300457 (CN) AL BA HR MK RS (74) Representative: Hryszkiewicz, Danuta et al (30) Priority: 25.08.2006 CN 200610015437 Kancelaria Patentowa ul. Jana z Kolna 38 PL-75-204 Koszalin (PL) (54) THE ANTIBIOTICS COMPOSITION COMPRISING BETA-LACTAM ANTIBIOTICS AND IONIC CHELATING AGENTS (57) The antibiotics composition comprising at least tors and buffers simultaneously. The composition can be one of beta-lactam antibiotics and at least one of ionic formulated with at least one of aminoglycoside antibiotics chelating agents used for inhibiting particulate formation, into solution for controlling microbial infection in a con- further comprising at least one of beta-lactamase inhib- tainer.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Sulbenicillin-Induced Kaliuresis in Man Abstract the Mechanism Of
    Japanese Journal of Physiology, 33, 811-820,1983 Sulbenicillin-induced Kaliuresis in Man Kimio TOMITA,* Osamu MATSUDA, Shinsuke SHINOHARA, Tatsuo SHIIGAI, and Jugoro TAKEUCHI Department of Internal Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, 113 Japan Abstract The mechanism of kaliuresis induced by massive antibiotic administration was studied using a-sulfobenzyl penicillin (SBPC). In experimental group (n=8), urinary electrolytes excretion were com- pared between following the infusion of 10 g SBPC in 200 ml water at a constant rate and following the infusion of 48 mmol of NaCI (equal to that contained in 10 g SBPC) in 200 ml water. For the control group, 96 mmol NaCI in 400 ml water was infused (n=5). In the experimental group, urinary Na (UNaV) and urinary K excretion (UKV) increased relative to the control period. In the control group, UKV was not increased although UNaV was increased (p <0.05). UKV following SBPC infusion was correlated with UNaV (p<0.05) and urinary SBPC excretion (p <0.05). The ratio of urinary anion gap to urinary cation [1-{urinary Cl concentration/(urinary Na concentrations urinary K concentration)}] was significantly increased following SBPC infusion (p<0.005) but not in the control group. This increase in anion gap is possibly due to urinary SBPC, which will be ionized over 90% as nonreabsorbable anion in maximally acidic urine. We conclude that the kaliuresis induced by massive SBPC administration in man is probably caused by the nonreabsorbable anion effect of SBPC itself. Key Words: kaliuresis, nonreabsorbable anion, antibiotics, sulbeni- cillin. Recently, treatment with massive doses (from 10 to 30 g per day) of antibiotics has been extensively applied to serious infections or infections in patients with malignant tumors.
    [Show full text]
  • Antimicrobial Composition
    Europa,schesP_ MM M II M MM 1 1 M Ml MM M Ml J European Patent Office .ha no © Publication number: 0 384 41 OBI Office europeen, desJ brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 17.05.95 © Int. CI.6: A61 K 31/545, A61 K 31/43, //(A61K31/545,31:43) © Application number: 90103266.4 @ Date of filing: 20.02.90 The file contains technical information submitted after the application was filed and not included in this specification © Antimicrobial composition. ® Priority: 21.02.89 JP 41286/89 9-1, Kamimutsuna 3-chome 14.04.89 JP 94460/89 Okazaki-shi, Aichi (JP) @ Date of publication of application: Inventor: Sanada, Mlnoru, c/o BANYU PHARM. 29.08.90 Bulletin 90/35 CO., LTD. OKAZAKI RES. LABORATORY, © Publication of the grant of the patent: 9-1, Kamimutsuna 3-chome 17.05.95 Bulletin 95/20 Okazaki-shi, Aichi (JP) © Designated Contracting States: Inventor: Nakagawa, Susumu, c/o BANYU CH DE FR GB IT LI NL PHARM. CO., LTD. OKAZAKI RES. LABORATORY, © References cited: 9-1, Kamimutsuna 3-chome EP-A- 0 248 361 Okazaki-shi, Aichi (JP) UNLISTED DRUGS, vol. 37, no. 2, February Inventor: Tanaka, Nobuo, c/o BANYU PHARM. 1985, Chatham, New Jersey, US; "Zienam CO., LTD. 250". 2-3, Nihonbashi Honcho 2-chome Chuo-ku, © Proprietor: BANYU PHARMACEUTICAL CO., Tokyo (JP) LTD. Inventor: Inoue, Matsuhisa 2-3, Nihonbashi Honcho 2-chome 3076-3, Oaza-Tokisawa 00 Chuo-ku, Tokyo (JP) Fujlmi-mura, Seta-gun, @ Inventor: Matsuda, Kouji, c/o BANYU PHARM. Gunma (JP) CO., LTD.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Separation and Purification of Pharmaceuticals and Antibiotics [Table IX-1-1] Principal Antibiotics Penicillin-G (Benzylpenicillin), Oxacillin, Chlox- 1
    Separation and Purification of Pharmaceuticals and Antibiotics [Table IX-1-1] Principal Antibiotics Penicillin-G (benzylpenicillin), Oxacillin, Chlox- 1. Antibiotics acillin, Dichloxacillin, Nafcillin, Methicillin, (1) Outline Amoxicillin, Ampicillin, Ticarcillin, Piperacillin, Penicillins aspoxicillin, Antibiotics are "chemical substances produced by microorganisms Ciclacillin, Sulbenicillin, Talampicillin, which, in minute quantities, inhibit or suppress the proliferation of other Bacampicillin, Pivmecillinam, lenampicillin, microorganisms". This is defined in 1942 by Selman Abraham Waksman β-Lactams Phenethicillin, Carbenicillin etc, in the USA. Antibiotics were developed in Britain following the discovery Cephalosporin C of Penicillin in 1929 by Alexander Fleming: He found that Blue mold, Cefazolin, Cefatrizine, Cefadroxil, Cefalexin, Cephalosporins Cefaloglycin, Cefalothin, Cefaloridine, Cefoxitin, Penicillium, dissolves Staphylococcus staphylococci and inhibits its Cefotaxime, Cefoperazone, Ceftizoxime, Cefmet- growth and he named the extract from Penicillium as Penicillin. Many azole, Cefradine, Cefroxadine etc. new antibiotics have been found since 1940’s, and there are more than Other β-lactams 1,500 antibiotics. Principal ones are listed in Table IX-1-1. Kanamycins Amikacin, Kanamycin, Dibekacin Most of these antibiotics are manufactured by fermentation or by Gentamycins, Gentamicin, Micronomicin semi-synthesis that combines fermentation and organic synthesis, though Sisomycins chloramphenicol is by synthesis. Fermentation is carried out by Acti- Streptomycins Streptomycin Aminoglycosides nomycetes, mold (hyphomycetes) or bacteria in culture media with glu- Spectinomycins Spectinomycin cose, sucrose, lactose, starch or dextrin as carbon source, with nitrate, Fradiomycins Fradiomycin, ammonium salt, corn steep liquor, peptone, meat extract or yeast extract Astromicins Astromicin as nitrogen source and with a little amount of inorganic salts. Erythromycin, Oleandomycin, Carbomycin, Penicillin-type antibiotics are manufactured by semi-synthesis, i.e.
    [Show full text]
  • Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
    TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals .................................................................................................................................................
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]